U.S. officials have given green light for two clinical trials testing of AstraZeneca’s cancer immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients.
The lift cancels hold imposed on the clinical trials following cases of bleeding.
The British drug maker said on Tuesday that one of the late-stage Phase III trials had already re-opened for new patients enrolment and the second was expected to resume recruitment shortly.
News of the partial hold on the trials, imposed at the end of last month, had hindered investors since durvalumab is AstraZeneca’s most important pipeline medicine. (NAN)
